669P TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas.
Affiliation
Department of Clinical Cancer Research, Oslo University Hospital and Norwegian Radium Hospital, Oslo, NorwayIssue Date
2017-09
Metadata
Show full item recordCitation
669P TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx369.053Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx369.053/4108756/669PTG01GMCSF-and-adjuvant-gemcitabine-in-patientsType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx369.053